home / stock / nnbxf / nnbxf short
Short Information | Nanobiotix SA (OTCMKTS:NNBXF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,056 |
Total Actual Volume | 2,490 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 5 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 103 |
Average Short Percentage | 23.74% |
Is there a NNBXF Short Squeeze or Breakout about to happen?
See the NNBXF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-04-2021 | $18.35 | $18.35 | $18.35 | $18.35 | 1,000 | 1,000 | 100% |
02-02-2021 | $18.3 | $18.3 | $18.3 | $18.3 | 500 | 500 | 100% |
12-11-2020 | $16.25 | $16.25 | $16.25 | $16.25 | 426 | 92 | 21.6% |
12-10-2020 | $14.8183 | $14.95 | $14.95 | $14.8183 | 214 | 114 | 53.27% |
12-09-2020 | $15.35 | $15.35 | $15.35 | $15.35 | 250 | 250 | 100% |
11-30-2020 | $15.25 | $15.25 | $15.25 | $15.25 | 100 | 100 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Nanobiotix SA Company Name:
NNBXF Stock Symbol:
OTCMKTS Market:
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial effi...
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilitie...
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy Confirmation of injection feasibility and favorable safety profile in completed ...